title: Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
authors.affiliation: US Oncology Research, Inc., Houston, TX 77090, USA.
authors.forename: Hemachandra
authors.initials: H
authors.lastname: Venkatesh
authors.forename: Nicholas
authors.initials: N
authors.lastname: Di Bella
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Flynn
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Vellek
authors.forename: Kristi A
authors.initials: KA
authors.lastname: Boehm
authors.forename: Lina
authors.initials: L
authors.lastname: Asmar
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine